Arcus Biosciences, Inc. (RCUS): Price and Financial Metrics


Arcus Biosciences, Inc. (RCUS): $37.68

1.71 (+4.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RCUS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

RCUS POWR Grades


  • RCUS scores best on the Value dimension, with a Value rank ahead of 69.06% of US stocks.
  • The strongest trend for RCUS is in Momentum, which has been heading down over the past 48 weeks.
  • RCUS ranks lowest in Growth; there it ranks in the 6th percentile.

RCUS Stock Summary

  • The price/operating cash flow metric for Arcus Biosciences Inc is higher than 95.51% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of 226.32%, Arcus Biosciences Inc's debt growth rate surpasses 96.02% of about US stocks.
  • Revenue growth over the past 12 months for Arcus Biosciences Inc comes in at 519.59%, a number that bests 98.4% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to RCUS, based on their financial statements, market capitalization, and price volatility, are CARA, CNCE, ANAB, ALPN, and KLDO.
  • Visit RCUS's SEC page to see the company's official filings. To visit the company's web site, go to www.arcusbio.com.

RCUS Valuation Summary

  • RCUS's price/sales ratio is 22.4; this is 489.47% higher than that of the median Healthcare stock.
  • RCUS's price/earnings ratio has moved up 2.8 over the prior 42 months.
  • RCUS's EV/EBIT ratio has moved up 2.4 over the prior 42 months.

Below are key valuation metrics over time for RCUS.

Stock Date P/S P/B P/E EV/EBIT
RCUS 2021-08-31 22.4 3.4 -10.5 -9.1
RCUS 2021-08-30 22.8 3.5 -10.7 -9.3
RCUS 2021-08-27 22.7 3.5 -10.6 -9.2
RCUS 2021-08-26 22.2 3.4 -10.4 -9.0
RCUS 2021-08-25 22.6 3.5 -10.6 -9.2
RCUS 2021-08-24 22.2 3.4 -10.4 -9.0

RCUS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RCUS has a Quality Grade of C, ranking ahead of 33.92% of graded US stocks.
  • RCUS's asset turnover comes in at 0.109 -- ranking 260th of 677 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows RCUS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.109 1 -0.432
2021-03-31 0.114 1 -0.447
2020-12-31 0.138 1 -0.423
2020-09-30 0.186 1 -0.442
2020-06-30 0.056 1 -0.927
2020-03-31 0.072 1 -0.819

RCUS Stock Price Chart Interactive Chart >

Price chart for RCUS

RCUS Price/Volume Stats

Current price $37.68 52-week high $42.36
Prev. close $35.97 52-week low $16.69
Day low $35.14 Volume 781,600
Day high $37.99 Avg. volume 584,638
50-day MA $31.45 Dividend yield N/A
200-day MA $31.31 Market Cap 2.69B

Arcus Biosciences, Inc. (RCUS) Company Bio


Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is based in Hayward, California.


RCUS Latest News Stream


Event/Time News Detail
Loading, please wait...

RCUS Latest Social Stream


Loading social stream, please wait...

View Full RCUS Social Stream

Latest RCUS News From Around the Web

Below are the latest news stories about Arcus Biosciences Inc that investors may wish to consider to help them evaluate RCUS as an investment opportunity.

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Companys Board of Directors granted five new employees options to purchase a total of 44,200 shares of the Companys common stock at an exercise price per share of $34.31, which was the closing price on September 8, 2021. The stock options were granted pursuant to the Compan

Business Wire | September 9, 2021

Arcus Biosciences to Participate at Upcoming Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming September 2021 virtual investor conferences. Citis 16th Annual Virtual Biopharma Conference, Friday, September 10 at 1:25 pm ET 2021 Cantor Virtual Global Healthcare Conference, Monday, September 27 at 4:40 pm ET A live audio webcast of the presentation will b

Business Wire | September 1, 2021

Arcus Biosciences Inc (RCUS): Price Now Near $27.89; Daily Chart Shows An Uptrend on 50 Day Basis

It''s been a feast for bears operating on an hourly timeframe, as rcus has now gone down 4 of the past 5 hours. The post Arcus Biosciences Inc (RCUS): Price Now Near $27.89; Daily Chart Shows An Uptrend on 50 Day Basis appeared first on ETF Daily News .

ETF Daily News | August 18, 2021

These Analysts Just Made A Substantial Downgrade To Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Forecasts

The analysts covering Arcus Biosciences, Inc. ( NYSE:RCUS ) delivered a dose of negativity to shareholders today, by...

Yahoo | August 8, 2021

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Lags Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -41.56% and -48.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 6, 2021

Read More 'RCUS' Stories Here

RCUS Price Returns

1-mo 27.64%
3-mo 37.22%
6-mo 30.70%
1-year 114.82%
3-year 170.30%
5-year N/A
YTD 45.15%
2020 157.03%
2019 -6.22%
2018 N/A
2017 N/A
2016 N/A

Continue Researching RCUS

Want to see what other sources are saying about Arcus Biosciences Inc's financials and stock price? Try the links below:

Arcus Biosciences Inc (RCUS) Stock Price | Nasdaq
Arcus Biosciences Inc (RCUS) Stock Quote, History and News - Yahoo Finance
Arcus Biosciences Inc (RCUS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8822 seconds.